AK112 high dose

DRUG2 trials

Sponsors

Akeso

Conditions

Ovarian CancerOvarian NeoplasmsPlatinum-sensitive Ovarian CancerRecurrent Ovarian CarcinomaRelapsed Ovarian Cancer

Phase 1

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

TerminatedNCT04999605

AkesoOvarian Cancer, Ovarian Neoplasms, Recurrent Ovarian Carcinoma +1

Start: 2021-06-24End: 2022-06-10Updated: 2024-01-05

Phase 2

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

RecruitingNCT06686030

AkesoPlatinum-sensitive Ovarian Cancer

Start: 2025-02-17End: 2028-07-31Target: 150Updated: 2025-04-16